Table 2.
Descriptive analysis of case‐based data collected in the case‐based module from participating hospitals in the pandemic influenza hospital surveillance, Germany, 2009–2010
| Recovered PI cases n = 43 | Fatal PI cases n = 16 | P | |||
|---|---|---|---|---|---|
| n | % | n | % | ||
| Age (years in median; range) | 41; 1–81 | 49; 14–58 | 0·35 | ||
| Men | 27 | 63 | 12 | 75 | 0·38 |
| Length of stay in hospital (days in mean; range) | 17; 0–69 | 18; 2–37 | 0·31 | ||
| ICU stay | 26 | 61 | 16 | 100 | 0·003 |
| Length of stay in ICU (days in mean; range) | 23; 1–58 | 18; 2–38 | 0·58 | ||
| Mechanical ventilation | 22 | 51 | 16 | 100 | <0·001 |
| ECMO | 7 | 16 | 12 | 75 | 0·008 |
| One or more underlying medical conditions | 31 | 72 | 14 | 88 | 0·31 |
| One or more complications | 28 | 65 | 16 | 100 | 0·006 |
| Pandemrix®‐vaccination | 1 | 3 | |||
| Oseltamivir therapy | 22* | 51 | 12 | 75 | 0·21 |
| Start of Oseltamivir therapy after the onset of symptoms (days in mean; range) | 4; 0–17* | 8; 0–22 | 0·04 | ||
| Zanamivir therapy | 8 | 19 | 9 | 56 | 0·009 |
| Start of Zanamivir therapy after the onset of symptoms (days in mean; range) | 12; 0–21 | 15; 3–36 | 0·7 | ||
| Antibiotic therapy | 28 | 65 | 15 | 94 | 0·012 |
*Two patients excluded: treatment 6 and 22 days before the onset of symptoms.